Inclusion Complex of Theophylline with β−Cyclodextrin: Influence of Method of Preparation by Behera , Anam
 Inclusion Complex of Theophylline with 
β−Cyclodextrin: Influence of Method of Preparation 
 
                                                     
A Dissertation 
Submitted in partial fulfilment 
 
 
FOR THE DEGREE OF 
MASTER OF SCIENCE IN CHEMISTRY 
 
 
 
Under The Academic Autonomy 
 
NATIONAL INSTITUTE OF TECHNOLOGY, ROURKELA 
 
By 
 
ANAM BEHERA 
Roll No. 413CY2004  
 
 
Under the Guidance of 
 
Dr. USHARANI SUBUDDHI 
 
DEPARTMENT OF CHEMISTRY 
 
 
 
 
 
NATIONAL INSTITUTE OF TECHNOLOGY 
ROURKELA – 769008, ODISHA 
 
i 
 
 
      
 
CERTIFICATE 
   
 
This is to certify that the project entitled “Inclusion Complex of Theophylline with 
β−Cyclodextrin: Influence of Method of Preparation” being submitted by Mr. Anam 
Behera (Roll No.: 413CY2004) to the Department of Chemistry, National Institute of 
Technology, Rourkela, Odisha, for the award of the degree of Master of Science is a record 
of bonafide research carried out under my supervision and guidance. To the best of my 
knowledge, the matter embodied in the report has not been submitted to any other University 
/ Institute for the award of any Degree or Diploma. 
 
 
 
 
Rourkela 
Date: 04−05−2015                                                                           Dr. Usharani Subuddhi 
                                                                                                              Dept. of Chemistry 
                                                                                                  National Institute of Technology 
                                                                                                                  Rourkela, Odisha 
 
 
 
 
 
 
 
 
 
 
 
ii 
 
ACKNOWLEDGEMENT 
   
 
With deep regards and profound respect, I avail the opportunity to express my deep sense of 
gratitude and indebtedness to Dr. Usharani Subuddhi , Department of Chemistry, National 
Institute of Technology, Rourkela, for introducing the present project topic and for her 
inspiring guidance, constructive criticism and valuable suggestions throughout the project 
work. I gratefully acknowledge her constant encouragement and help in different ways to 
complete this project successfully. 
 
My sincere regards to Dr. N. Panda (HOD, Dept of Chemistry) and all the faculty members, 
Department of Chemistry, NIT Rourkela for their enthusiasm in promoting the research in 
chemistry and for their kindness and dedication to students. I would also like to convey my 
sincere thanks to Prof. R. K. Patel and Mr. Sandeep for allowing me use the microwave.   
 
I also acknowledge the support of Miss Shubraseema, Miss Smruti Snigdha and Mr. 
Patitapabana for their constant guidance and help in various ways while forming the project 
work and to my classmate Rajkishore for his encouragement. Last but not the least, I take the 
privilege to express my deep sense of gratitude to my Parents, for selflessly extending their 
ceaseless help and moral support at all times. 
 
 
 
 
Anam Behera 
 
 
iii 
 
 
ABSTRACT 
Inclusion complexes of Theophylline (THP) with β-cyclodextrin (β−CD) were prepared in 
order to improve the solubility and bioavailability of the poorly water soluble drug. Solution 
phase interaction was studied by UV-Vis and Fluorescence techniques. The linear Benesi–
Hildebrand plot indicated the formation of only one type of complex with a host-guest 
composition of 1:1 in the solution. The effect of method of preparation of the THP-β−CD 
inclusion complexes (ICs) was investigated. The ICs were prepared by the conventional 
methods of physical mixing (PM), kneading (KN), co-precipitation (CP) and freeze drying 
(FD) and also by the novel approach of microwave irradiation method (MW). The solid 
inclusion complexes were characterized by various spectroscopic techniques such as FTIR, 
XRD, DSC, SEM and 1H NMR. The characterization techniques indicated the formation of 
true inclusion complexes in case of CP, FD and MW. The in vitro dissolution rate of THP 
was considerably enhanced when the inclusion complexes were employed. Therefore, the 
bioavailability of THP can be improved significantly by forming inclusion complexes with 
cyclodextrin. 
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CHAPTER 1 
INTRODUCTION 
1.1 Cyclodextrins 
Cyclodextrins (CD) are cyclic oligosaccharides derived from starch containing six (α-CD), 
seven (β-CD), eight (γ-CD), nine (δ-CD) or ten (ɛ-CD) or more (α-1, 4)-linked α-D-
glucopyranose units (Figure 1).  Cyclodextrins (CDs), with lipophilic inner cavities and 
hydrophilic outer surfaces, are capable of interacting with a large variety of guest molecules 
to form non-covalent inclusion complexes. Chemically they are cyclic oligosaccharides 
containing at least 6 D-(+) glucopyranose units attached by α glucosidic bonds [1].  
Table 1. Characteristics of natural cyclodextrins; α-CD, β-CD and γ-CD 
 
Cyclodextrin 
 
Molecular 
weight 
 
Number of 
glucose units 
Dimensions (nm)  
Solubility 
 (g/ 100mL) H          OD          ID 
α-Cyclodextrin (α-CD) 972 6 0.78       1.37         0.57 14.5 
β-Cyclodextrin (β-CD) 1135 7 0.78       1.53         0.78 1.85 
γ-Cyclodextrin (γ-CD) 1297 8 0.78       1.69         0.95 23.2 
H: Height, OD: Outer diameter, ID: Inner diameter 
 
Figure 1. Geometrical representation of α−CD, β−CD and γ−CD molecules. 
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CDs adapt to the shape of a truncated cone rather than a perfect cylinder because of the chair 
conformation of the glucopyranose units; the primary and secondary hydroxyl groups 
oriented outwards (Fig. 2).   
 
Figure 2. Truncated cone/ torus shape of cyclodextrins. 
As a result of their molecular structure and shape, they possess a unique ability to act as 
molecular containers and can entrap guest molecules in their internal cavity. No covalent 
bonds are formed or broken during drug−CD complex formation, and upon dilution, the 
complexes readily dissociate and free drug molecules remain in equilibrium with the 
molecules bound within the CD cavity. 
CDs with lower than 6 glucose units cannot be formed due to steric hindrances while the 
higher homologues with more than 9 units are difficult to purify. The cavity size of α-CD is 
insufficient for many drugs while γ-CD is very expensive. In general, δ-CD has weaker 
complex formation ability than the conventional CDs. β-CD has been widely employed in 
pharmaceutical applications for the entrapment for a variety of molecules including drugs due 
to its suitable cavity size and ready availability [2].   
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Chemically modified CD derivatives have been prepared with a view to extend the physico-
chemical properties and the inclusion efficiency of the parent CDs. Several amorphous, non   
crystallisable CD derivatives with enhanced aqueous solubility, physical and microbiological 
stability and reduced parenteral toxicity have been developed by chemical modification of 
CD [3, 4]. Some of the commonly used CD derivatives have been listed below in the Table 2. 
Table 2. Commonly used abbreviations for CD derivatives 
Cyclodextrin (CD) Abbreviation 
Hydroxyethyl-β-CD HE-β-CD 
Hydroxypropyl-β-CD HP-β-CD 
Sulfobutylether-β-CD SE-β-CD 
Methyl-β-CD M-β-CD 
Dimethyl-β-CD DM-β-CD (DIMEB) 
Carboxymethyl-β-CD CM-β-CD 
Carboxymethyl ethyl-β-CD CME-β-CD 
Glucosyl-β-CD G1-β-CD 
Maltosyl-β-CD G2-β-CD 
Tri-O-methyl-β-CD TRIMEB 
Tri-O-ethyl-β-CD TE-β-CD 
Tri-O-butyryl-β-CD TB-β-CD 
Tri-O-valeryl-β-CD TV-β-CD 
  
Factors Affecting Inclusion Complexation 
The type of CD employed can influence the formation of inclusion complex as well its 
performance [5]. For the inclusion phenomenon, the cavity size of CD should be appropriate 
to accommodate the guest molecule [6].  Compared with neutral CDs, the complexation will 
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be efficient when the CD and the drug carry opposite charges. In case of ionisable drugs, the 
presence of charge plays a significant role in the drug/ CD complexation and a change in the 
solution pH can vary the overall association constant.. 
Higher temperature has been reported to decrease the magnitude of the apparent binding 
constant of the drug−CD complex and the effect has been attributed to reduction in drug−CD 
interaction forces. The list of factors affecting CD complexation has been compiled in Table 
3. [7, 8] 
Table 3. List of factors affecting inclusion complexation 
Factor Drug CDs used Observation 
Type of CD Ketoprofen  
Albendazole 
β-CD, M-β-CD Solubility enhancement 
Cavity size Digitoxin β-CD, HP-β-CD Enhanced solubility 
pH  Piroxicam β-CD Effective complexation at low pH 
Temperature Sulindac β-CD Lower temperature increases binding 
constant 
 
Effects of CD on Drug Properties in Formulations 
• Improved Drug Solubility and Dissolution 
CDs play a vital role in improving the apparent drug solubility or the dissolution rate through 
inclusion complexation by acting as hydrophilic carriers for drugs. Some common examples 
of CD applications as drug solubilising agents are summarized in Table 4. 
Table 4. List of CD-enhanced solubility and dissolution of drugs 
CD Drugs 
α-CD Praziquantel 
β-CD Naproxen, Ibuprofen, Lorazepam, 
Ketoprofen, Piroxicam etc 
γ−CD Digoxin, Omeprazole 
HP-β-CD Albendazole, Rutin, Itraconazole, Ketoprofen 
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• Enhanced Drug Bioavailability 
In case of hydrophobic drugs, CDs increase the permeability by increasing drug solubility, 
dissolution and thus making the drug available at the surface of the biological barrier, from 
where it partitions into the membrane without disrupting the lipid layers of the barrier [9].   
• Control of Drug Release 
The combined use of CD inclusion complexes and CDs conjugate can be helpful for 
designing various kinds of time-controlled type oral drug delivery formulations. The release 
of drug from the drug/CDs conjugate after oral administration shows typical delayed-release 
behaviour. Therefore, when the CD conjugates are combined with other different release 
preparations, more advanced and optimized drug release system, securing balanced oral 
bioavailability, and prominent therapeutic efficacy can be achieved [10]. 
• Site-specific Drug Delivery 
CDs have the inherent property to be fermented to small saccharides by colonic microflora 
and thus absorbed as maltose or glucose in the large intestine. This biological property of 
CDs can be exploited for site-specific delivery of drugs to colon [11].  
• Improved Drug Stability 
Cyclodextrin complexation provides molecular shielding by encapsulating labile drug 
molecules at molecular level. Thus insulate them against various degradation processes due 
to heat and light and increase the shelf life of drugs [12]. 
• Improved Drug Efficacy 
CDs have been used to reduce the irritation caused by drugs [13]. The increased drug efficacy 
and potency (i.e., reduction of the dose required for optimum therapeutic activity), caused by 
CD-increased drug solubility, may reduce drug toxicity by making the drug effective at lower 
doses. 
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1.2 Theophylline 
Theophylline (1, 3-dimethylxantine), TPH (Figure 3), is a poorly water soluble purine 
alkaloid. It is widely used in medicinal and pharmaceutical fields in the treatment of diseases 
related to respiratory problems like asthma, emphysema and chronic obstructive pulmonary 
diseases.  
 
Figure 3. Chemical structure of Theophylline (THP). 
As a member of the xanthine family, THP bears structural and pharmacological resemblance 
to theobromine and caffeine. 
The main actions of THP involve [14]: 
• relaxing bronchial smooth muscle 
• increasing heart muscle contractility and efficiency; as a positive inotropic 
• increasing heart rate: (positive chronotropic) 
• increasing blood pressure 
• increasing renal blood flow 
• anti-inflammatory effects 
• central nervous system stimulatory effect mainly on the medullary respiratory centre. 
However the use of THP is limited by its very rapid absorption [15] and conversion to 
inactive metabolites [16]. The metabolic product of THP is methyluric acids such as 1,3-
dimethyl uric acid and 1-methyl uric acid in urine. Inactive metabolites may cause 
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undesirable side effects that can harm human health [17]. Moreover, the aqueous solubility of 
THP is very low because of which the formulation of this drug is challenging [18]. 
1.3 Objectives 
The specific objectives of the present study are:   
• To study of solution phase inclusion process of THP with β‒CD by UV-Vis and 
Fluorescence spectroscopic methods. 
• Preparation of solid inclusion complexes (IC) of THP with β‒CD by the conventional 
methods such as physical mixing, kneading, co-precipitation and freeze drying and 
also by the microwave irradiation method. 
• Characterisation of ICs by various spectroscopic techniques such as FTIR, XRD, 
DSC, SEM and 1H NMR techniques. 
• To study the dissolution characteristics of THP and the ICs. 
• Compare the efficacy of the methods of preparation of ICs for better and improved 
characteristics. 
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CONCLUSIONS 
• The solid inclusion complexes of THP with β−CD have been prepared by the 
conventional methods of physical mixing, kneading, co-precipitation and freeze 
drying and also by the novel approach of microwave irradiation method. 
• Solution phase interaction was studied by UV-Vis and Fluorescence techniques. 
• The linear Benesi–Hildebrand plot indicated the formation of only one type of 
complex with a host-guest composition of 1:1 in the solution.  
• The solid inclusion complexes were characterized by various spectroscopic 
techniques such as FTIR, XRD, DSC, SEM and 1H NMR.  
• The characterization techniques indicated the formation of true inclusion complexes 
in case of CP, FD and MW. 
• The in vitro dissolution rate of THP was significantly enhanced when the inclusion 
complexes were employed. 
• Therefore, the bioavailability of THP can be improved significantly by forming 
inclusion complexes with cyclodextrin. 
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